2. As of noon trading, Bristol-Myers Squibb Company ( BMY) is down $0.36 (-0.9%) to $41.62 on average volume. Thus far, 5.0 million shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 9.4 million shares. The stock has ranged in price between $41.26-$42.14 after having opened the day at $41.85 as compared to the previous trading day's close of $41.98.

Bristol-Myers Squibb Company, a biopharmaceutical company, discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products that help patients prevail over serious diseases worldwide. Bristol-Myers Squibb Company has a market cap of $70.7 billion and is part of the health care sector. Shares are up 28.8% year to date as of the close of trading on Thursday. Currently there are 6 analysts that rate Bristol-Myers Squibb Company a buy, 1 analyst rates it a sell, and 12 rate it a hold.

TheStreet Ratings rates Bristol-Myers Squibb Company as a buy. The company's strengths can be seen in multiple areas, such as its good cash flow from operations, expanding profit margins, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Bristol-Myers Squibb Company Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Novartis CEO Joe Jimenez to Step Down in 2018

FDA Greenlights Novartis' Gene Therapy for Leukemia

Novartis' CAR-T Gene Therapy Receives FDA Approval

Novartis AG, Sirius XM Radio, Coupa Software: 'Mad Money' Lightning Round

August's Inexplicable Selloffs Are Here: Cramer's 'Mad Money' Recap (8/17/17)